Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Progress realized: trends in HIV-1 viral load and CD4 cell count in a tertiary-care center from 1999 through 2011.

Gale HB, Rodriguez MD, Hoffman HJ, Benator DA, Gordin FM, Labriola AM, Kan VL.

PLoS One. 2013;8(2):e56845. doi: 10.1371/journal.pone.0056845. Epub 2013 Feb 20.

2.

Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.

Dorrucci M, Rezza G, Porter K, Phillips A; Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration.

J Infect Dis. 2007 Feb 15;195(4):525-34. Epub 2007 Jan 10.

PMID:
17230412
3.

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration.

Lancet. 2004 Jul 3-9;364(9428):51-62.

PMID:
15234856
4.
6.

Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients.

Valentine ME, Jackson CR, Vavro C, Wilfert CM, McClernon D, St Clair M, Katz SL, McKinney RE Jr.

Pediatr Infect Dis J. 1998 Jan;17(1):18-23.

PMID:
9469389
7.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

8.

Gender difference in HIV-1 RNA viral loads.

Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, van Sighem AI, de Wolf F, Rode RA, Anderson RM.

HIV Med. 2005 May;6(3):170-8.

9.

Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa.

Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E.

Clin Infect Dis. 2009 Sep 15;49(6):956-64. doi: 10.1086/605503.

10.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

AIDS. 2006 May 12;20(8):1117-23.

PMID:
16691062
11.

Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 x 10(6)/l.

García F, Vidal C, Gatell JM, Miró JM, Soriano A, Pumarola T.

AIDS. 1997 Jan;11(1):53-7.

PMID:
9110075
12.

Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.

Herbeck JT, Müller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, Gras L, Günthard HF, Jacobson LP, Mullins JI, Gottlieb GS.

AIDS. 2012 Jan 14;26(2):193-205. doi: 10.1097/QAD.0b013e32834db418.

13.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
14.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
15.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
16.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
17.

Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.

Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Souala MF, Costagliola D; French Hospital Database on HIV ANRS CO4.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):422-6. doi: 10.1097/QAI.0b013e3181ab6ec1.

PMID:
19521249
18.

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A.

AIDS. 1999 May 28;13(8):951-6.

PMID:
10371176
19.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
20.

Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients.

Campo J, Del Romero J, Castilla J, García S, Rodríguez C, Bascones A.

J Oral Pathol Med. 2002 Jan;31(1):5-10.

PMID:
11896816

Supplemental Content

Support Center